Trial
NCT03371381
An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Adenocarcinoma of Lung
Intervention
JNJ-64041757
Why stopped
Development of JNJ-64041757 in combination with nivolumab discontinued due to lack of clinical benefit observed in the Phase 1b portion of the study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-04